HCM — HUTCHMED (China) Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1648257 ·
Hong Kong
Last close
$14.40
Market Cap
$2.50B
52W High
$16.33
52W Low
$9.77
ADV30
47,574
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 1,753,097,000 | 71,330,000 | 501,835,000 |
| Jun 2025 | — | — | — | — | 1,775,940,000 | — | 534,017,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-378,643,000
Inventory
$41,129,000
Receivables
—
ST Investments
$1,295,945,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$549,121,984
EBITDA
$-20,515,000
Free Cash Flow
$-18,880,250
Enterprise Value
$960,541,632
Total Cash
$1,376,455,936
Total Debt
$94,508,000
Shares Out
173,814,168
Trailing EPS
$0.10
Book Value
$7.25
ROE
1.5%
ROA
-1.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 548,512,000 | -35,700,000 | 456,909,000 | 1,753,097,000 | 501,835,000 | 1,237,926,000 | -64,657,000 |
| Dec 2024 | 630,201,000 | -40,610,000 | 37,729,000 | 1,274,196,000 | 502,343,000 | 759,929,000 | 497,000 |
| Dec 2023 | 837,999,000 | 21,509,000 | 100,780,000 | 1,279,773,000 | 536,386,000 | 730,541,000 | 219,258,000 |
| Dec 2022 | 426,409,000 | -406,259,000 | -360,835,000 | 1,029,445,000 | 392,575,000 | 610,367,000 | -268,599,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.26
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $13.99 · call volume: 10 · put volume: 10
Expected Move to 2027-02-19:
±$5.38
(38.42%) —
implied range
$8.61 –
$19.36
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XNCR | Xencor Inc | $2.59B | $34.50 | — |
| MBX | MBX Biosciences, Inc. | $2.64B | $53.10 | — |
| IDYA | IDEAYA Biosciences, Inc. | $2.65B | $27.40 | — |
| RCUS | Arcus Biosciences, Inc. | $2.36B | $16.39 | — |
| NAMS | NewAmsterdam Pharma Co N.V. | $2.33B | $19.39 | — |
News headlines (Yahoo Finance, 1h cache)
HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
2026-11-19 00:00 · Yahoo
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
2026-11-16 04:00 · Yahoo
HUTCHMED (China) (AIM:HCM) Extends Lung Cancer Filing Run As Undervalued View Holds
2026-11-06 01:21 · Yahoo
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
2026-11-05 00:00 · Yahoo
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
2026-11-02 00:00 · Yahoo
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
2026-10-29 00:00 · Yahoo
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
2026-10-27 00:00 · Yahoo
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
2026-10-26 08:30 · Yahoo
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
2026-10-26 00:00 · Yahoo
UPDATE – International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 12, 2026
2026-11-09 16:56 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.